Xenon imaging study for pulmonary hypertension patients on sotatercept
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with pulmonary arterial hypertension (PAH) confirmed by a heart catheterization
- You are currently on a stable dose of PAH medication for at least 90 days
- You are willing to have an MRI scan (no metal implants, no severe claustrophobia)
- If you are a woman who can become pregnant, you must have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special MRI scan with xenon gas to take detailed images of how blood moves through your lungs. It aims to see if this imaging can help doctors better understand and manage pulmonary hypertension, which is high blood pressure in the lungs.
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
This Phase 2 trial is for adults with pulmonary hypertension who are on the lung transplant waiting list at Duke. It aims to test whether the study treatment can improve lung pressure and related health outcomes, while using things like MRI to monitor changes.
This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.